<DOC>
	<DOCNO>NCT01152216</DOCNO>
	<brief_summary>An open-label extension study CONCERT ( DIM18 ) protocol evaluate safety dimebon ( latrepirdine ) subject With Mild-to-Moderate Alzheimer 's Disease Donepezil .</brief_summary>
	<brief_title>An Extension CONCERT Protocol ( DIM18 )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Successful completion 12 month DIM18 CONCERT study Mildtomoderate Alzheimer 's disease Probable AD , Diagnostic Statistical Manual Mental DisordersIVText Revised ( DSMIVTR ) MiniMental State Exam ( MMSE ) score 12 24 , inclusive Stable donepezil least 6 month Other cause dementia Major structural brain disease Unstable medical condition significant hepatic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>